“Biotherapeutic Immunomodulation as a Countermeasure to Hyperinflammatory Tissue Damage

04. June 2015

“Biotherapeutic Immunomodulation as a Countermeasure to  Hyperinflammatory Tissue Damage – A Double-Blind, Phase 1 Human Study of Osteoarthritis, with Surprisin

Presentation and Research Paper presented at the PharmaLunch May, 2015 of the Swiss Academy of Pharmaceutical Sciences in Basel, Switzerland

Steven Taub, Research and Development Manager, Cardiovascular Surgery Department, Centre Hospitalier Universitaire Vaudois, CHUV,  Lausanne

 

 

You might also like